In mice bearing KRAS-positive and TP53-negative NSCLC tumor xenograft, two immunogenic chemotherapeutic drugs (oxaliplatin and cyclophosphamide) were shown to strongly enhance T cell infiltration of the tumors and sensitize them to subsequent checkpoint inhibition targeting both CTLA-4 and PD-1 (115). This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.